Loading
ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma and 4 more.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A.
Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.92, animal model 0.27, genetic association 0.41, somatic mutation 0.94). IntOGen calls it a driver in 13 cohorts (1 activating, 12 loss-of-function), covering Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Prostate Adenocarcinoma, Stomach Adenocarcinoma and others.
In plain words · ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma and 4 more.
ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma and 4 more.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases.
No product in this corpus aims at ACVR2A yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
First described 1991. Earliest sequence paper UniProt cites for the protein: Geiser A.G., 1991. Source.
Sources: HGNC HGNC:173 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P27037 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000121989 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.64, gastric cancer 0.56 (GraphQL API, CC0)); IntOGen ACVR2A (driver in 13 cohorts (Act 1, LoF 12); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6. Location: Cell membrane (UniProt). Locus 2q22.3-q23.1 (HGNC).
Query for this target: (TITLE:"ACVR2A" OR ABSTRACT:"ACVR2A" OR TITLE:"activin A receptor type 2A" OR ABSTRACT:"activin A receptor type 2A" OR TITLE:"Activin receptor type-2A" OR ABSTRACT:"Activin receptor type-2A" OR TITLE:"ACTRII" OR ABSTRACT:"ACTRII" OR TITLE:"ACVR2" OR ABSTRACT:"ACVR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACVR2A, not a curated reading list.
Shares TGF-β signalling, IntOGen, Gastric & gastro-oesophageal junction cancer, Open Targets Platform.
Shares TGF-β signalling, Mismatch repair & microsatellite instability, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares TGF-β signalling, IntOGen, Open Targets Platform.
Shares Cutaneous squamous cell carcinoma, IntOGen, Open Targets Platform.
Shares Mismatch repair & microsatellite instability, Open Targets Platform.
Shares Cutaneous squamous cell carcinoma, IntOGen.
Shares TGF-β signalling, Mismatch repair & microsatellite instability, Colorectal cancer.
Shares Mismatch repair & microsatellite instability, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Open Targets Platform.